Berberine Protects Against Lipopolysaccharide-induced Intestinal Injury in Mice Via Alpha 2 Adrenoceptor-independent Mechanisms
Overview
Authors
Affiliations
Aim: To investigate the mechanisms responsible for the protective action of berberine (Ber) against gut damage in endotoxemic mice.
Methods: Male BALB/c mice were administered intragastrically with distilled water (0.1 mL/10 g), Ber (50 mg/kg) alone, yohimbine (2 mg/kg) alone, or Ber (50 mg/kg) in combination with yohimbine (2 mg/kg) for 3 d. On the third day, lipopolysaccharide (LPS, 18 mg/kg) or normal saline was intraperitoneally injected one hour after the intragastric administration. Following the treatment, intestinal injury in the ileum was histopathologically accessed; enterocyte apoptosis was examined using TUNEL method; Toll-like receptor 4 (TLR4) mRNA expression was measured using RT-PCR assay; inhibitor protein-κBα (I-κBα) phosphorylation and myeloperoxidase content were examined using Western blloting. The macrophage inflammatory protein-2 (MIP-2) production was measured using ELISA assay.
Results: Mice challenged with LPS caused extensive ileum injury, including a significantly increased injury score, decreased intestinal villus height, reduced gut mucosal weight and increased intestinal permeability. Furthermore, LPS significantly induced enterocyte apoptosis, increased TLR4 mRNA expression, I-κBα phosphorylation, MIP-2 production and myeloperoxidase content in the ileum. Pretreatment with Ber significantly alleviated all the alterations in the ileum in the endotoxemic mice. Pretreatment with the α2-adrenoceptor antagonist yohimbine did not block the protective action of Ber against LPS-induced intestinal injury. In addition, treatment with yohimbine alone did not prevent LPS-induced intestinal injury.
Conclusion: Pretreatment with Ber provides significant protection against LPS-induced intestinal injury in mice, via reducing enterocyte apoptosis, inhibiting the TLR4-nuclear factor κB-MIP-2 pathway and decreasing neutrophil infiltration that are independent of α2-adrenoceptors.
Nguyen D, Duong T, Nguyen T, Nguyen H, Nguyen C ACS Omega. 2024; 9(50):50012-50023.
PMID: 39713661 PMC: 11656388. DOI: 10.1021/acsomega.4c09518.
Kim S, Lee R, Yoon J, Cheong H, Ra C, Rhee K Animals (Basel). 2024; 14(13).
PMID: 38998031 PMC: 11240726. DOI: 10.3390/ani14131919.
Smriti , Singla M, Gupta S, Porwal O, Binjawhar D, Sayed A Front Pharmacol. 2023; 14:1218625.
PMID: 37492081 PMC: 10364480. DOI: 10.3389/fphar.2023.1218625.
Recent Advances in Biologically Active Ingredients from Natural Drugs for Sepsis Treatment.
Zheng Z, Song X, Shi Y, Long X, Li J, Zhang M Comb Chem High Throughput Screen. 2023; 27(5):688-700.
PMID: 37254548 DOI: 10.2174/1386207326666230529101918.
Berberine in Sepsis: Effects, Mechanisms, and Therapeutic Strategies.
Lv T, Zhang C, Hu L, Wang C, Li S, Wang H J Immunol Res. 2023; 2023:4452414.
PMID: 36741234 PMC: 9891819. DOI: 10.1155/2023/4452414.